Edition:
India

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

10.59USD
7 Aug 2020
Change (% chg)

$-0.11 (-1.03%)
Prev Close
$10.70
Open
$10.70
Day's High
$10.82
Day's Low
$10.46
Volume
9,470
Avg. Vol
149,056
52-wk High
$15.00
52-wk Low
$2.09

Summary

Name Age Since Current Position

Mitchell Gold

53 2017 Executive Chairman of the Board, Chief Executive Officer

Stanford Peng

49 2019 President and Head of Research and Development

Paul Rickey

41 2019 Chief Financial Officer, Senior Vice President, Corporate Secretary

Wayne Gombotz

58 2019 Chief Technology Officer

Jay Venkatesan

48 2018 Director

Robert Conway

66 2015 Independent Director

Xiangmin Cui

51 2019 Independent Director

Christopher Peetz

41 2018 Independent Director

Paul Sekhri

62 2016 Independent Director

Peter Thompson

60 2017 Independent Director

James Topper

58 2017 Independent Director

Laurence Watts

2019 IR Contact Officer

Biographies

Name Description

Mitchell Gold

Dr. Mitchell H. Gold M.D. serves as Executive Chairman of the Board, Chief Executive Officer of the Company. He has served as our executive chairman, chief executive officer and a member of our board of directors since the completion of the merger of Nivalis Therapeutics, Inc. (which we refer to as Nivalis) and Alpine Immune Sciences, Inc. (which we refer to as Private Alpine) in July 2017 and prior to the merger served as Private Alpine’s chief executive officer since June 2016 and as Private Alpine’s executive chairman and member of Private Alpine’s board of directors since January 2015. Prior to co-founding Private Alpine, Dr. Gold was Chairman and Founder of Alpine Biosciences, a privately-held biotech company, from 2012 to 2014. From 2001 to 2012, Dr. Gold served in a variety of roles with Dendreon Corporation (which was acquired by Valeant Pharmaceuticals International, Inc. through an asset purchase agreement), including President, Chief Executive Officer, and Chairman of the board of directors. Earlier in his career, Dr. Gold served as Vice President of Business Development at Data Critical from 2000 to 2001. From 1995 to 2000, Dr. Gold was President and Chief Executive Officer of Elixis Corporation. Dr. Gold is currently a Managing Partner at Alpine BioVentures. Dr. Gold holds an M.D. from Rush Medical College of Rush University Medical Center and a B.S. in Biology from the University of Wisconsin.

Stanford Peng

Dr. Stanford L. Peng M.D., Ph.D. serves as President and Head of Research and Development of the Company. He was serves as Executive Vice President - Research and Development, Chief Medical Officer of the company. He has as served as our executive vice president of research and development and chief medical officer since the completion of the Merger in July 2017 and previously served as Private Alpine’s chief medical officer From September 2016 to February 2017 and as Private Alpine’s executive vice president of research and development and chief medical officer since February 2017. Prior to joining Private Alpine, Dr. Peng was chief medical officer and head of clinical development at Stemcentrx, providing strategic oversight of the company’s clinical and translational programs from 2015 to 2016. Previously, Dr. Peng was executive medical director at Seattle Genetics where he developed multiple programs for antibody-drug conjugates from 2014 to 2015. Earlier in his career, he directed translational research and auto-immune related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute from 2009 to 2014 and served as senior director, clinical research and exploratory development at Roche from 2005 to 2008. Between 2009 and 2014, Dr. Peng also served as member physician at Virginia Mason Medical Center. Dr. Peng served as an assistant professor at the Washington University School of Medicine from 2002 to 2005. From 2008 to 2009, Dr. Peng served as senior director at ARYx Therapeutics, Inc. (Nasdaq: ARYX). Dr. Peng received an M.D. and Ph.D. in biology from the Yale University School of Medicine and a B.A. in music and B.S. in biological sciences from Stanford University.

Paul Rickey

Mr. Paul Rickey CPA serves as Chief Financial Officer, Senior Vice President, Corporate Secretary of the Company. He has served as our senior vice president and chief financial officer since the completion of the Merger in July 2017 and previously served as Private Alpine’s senior vice president and chief financial officer since April 2017. Mr. Rickey is an experienced executive who has spent over 16 years guiding financial strategy in the life sciences and technology industries. Prior to his joining Private Alpine in 2017, Mr. Rickey served as chief financial officer of Sound Pharmaceuticals, overseeing finance, accounting and human resources. Before joining Sound Pharmaceuticals in 2016, Mr. Rickey was vice president of finance and administration of Immune Design Corp., (Nasdaq:IMDZ) a publicly traded biotechnology company, where he helped complete the company’s private offerings, initial public offering, and follow-on financing, and also oversaw the corporate development, accounting and human resource functions. Before joining Immune Design in 2009, Mr. Rickey was corporate controller of Northstar Neuroscience, a publicly-traded medical device company, where he managed the company’s finance and accounting groups following Northstar’s initial public offering. Prior to his role at Northstar Neuroscience, Mr. Rickey was the accounting manager for Mobliss, Inc., a mobile technology company that was sold to Index Corp., of Japan. Mr. Rickey started his finance career at Ernst & Young LLP. Mr. Rickey graduated from the University of Washington with a B.A. and Masters in Professional Accounting and is a certified public accountant.

Wayne Gombotz

Dr. Wayne R. Gombotz Ph.D. serves as Chief Technology Officer of the Company. Dr. Gombotz has more than 30 years' experience in the biotech and pharma industries and most recently served as the Chief Development Officer at Immune Design. As Chief Development Officer at Immune Design, Dr. Gombotz was responsible for advancing several immuno-oncology products from bench to pivotal clinical trials. Prior to Immune Design, He held senior roles at Omeros Corporation, Corixa Corporation, and Amgen (formerly Immunex), where he played a major role in the development and launch of ENBREL®, one of the top-selling drugs for psoriasis and multiple arthritis conditions. Dr. Gombotz currently serves as an Advisory Board Member for the University of Washington's Department of Bioengineering and was a recent recipient of the University of Washington College of Engineering's 2019 Diamond Award for Distinguished Achievement in Industry. Dr. Gombotz holds a PhD and MS in Bioengineering from the University of Washington and a BA in biology from Colby College.

Jay Venkatesan

Dr. Jay R. Venkatesan M.D. serves as Director of the Company. He served as Alpine’s Chief Executive Officer from November 2015 to June 2016 before transitioning to Alpine’s President in June 2016. Dr. Venkatesan has served as a member of Alpine’s board of directors since November 2015. Prior to joining Alpine, Dr. Venkatesan was the Executive Vice President and General Manager of Oncothyreon, Inc. (now Cascadian Therapeutics) from August 2014 to May 2015 following Oncothyreon’s acquisition of Alpine Biosciences, where he served as co-founder and Chief Executive Officer. Previously, Dr. Venkatesan was the Founder, Portfolio Manager, and Managing Director of Ayer Capital Management, a global healthcare equity fund from 2008 to 2013. Prior to that, he was a Director at Brookside Capital Partners from 2002 to 2007. Earlier in his career, Dr. Venkatesan was involved in healthcare investing at Partricof & Co. Ventures from 1995 to 1996 and consulting at McKinsey & Company from 1993 to 1995. In addition, Dr. Venkatesan currently serves on the board of directors of Iovance Biotherapeutics (NASDAQ: IOVA) (formerly Lion Biotechnologies), Transplant Genomics, CellBioTherapy, and Exicure Therapeutics. Dr. Venkatesan received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. in Chemistry from Williams College. Dr. Venkatesan is currently a Managing Partner at Alpine BioVentures, GP, LLC, a Delaware limited liability company, which is a general partner of Alpine Immunosciences, L.P., a Delaware limited partnership. In addition, Dr. Venkatesan is also a limited partner of Alpine Immunosciences, L.P. As a result of the Merger, Alpine Immunosciences, L.P., is currently a holder of more than 5% of the Company’s outstanding common stock.

Robert Conway

Mr. Robert E. Conway CPA serves as Independent Director of the Company. He has served as a member of our board of directors since April 2015. From 1999 to 2012, Mr. Conway served as the Chief Executive Officer and member of the board of directors of Array BioPharma (Nasdaq: ARRY), a publicly traded biopharmaceutical company. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, from 1996 to 1999. From 1979 until 1996, Mr. Conway held various executive positions for Corning Inc. (NYSE: GLW), including Corporate Vice President and General Manager of Corning Hazleton, a contract research organization. Since 2013, Mr. Conway has served on the board of directors of ARCA BioPharma (Nasdaq: ABIO), a publicly traded biopharmaceutical company, and was elected Chairman in June 2014. From 2004 to 2013, Mr. Conway served on the boards of directors of PRA International (Nasdaq: PRAH), which was a public company for a portion of his tenure there, and Bracket Corp., a private company. Mr. Conway serves as the Chairman of Wall Family Enterprise, a leading library and educational supplies company. In addition, Mr. Conway is a member of the Strategic Advisory Committee of Genstar Capital. Mr. Conway received a B.S. in accounting from Marquette University in 1976.

Xiangmin Cui

Mr. Xiangmin Cui Ph.D. serves as Independent Director of the Company. Dr. Cui has served as managing director of Decheng Capital, an investment firm focused on life sciences companies, since he founded the firm in 2011. Prior to founding Decheng, Dr. Cui was an investment partner at Bay City Capital, an international life science venture capital firm in San Francisco. Dr. Cui was previously director of strategic investment for the Southern Research Institute, a not-for-profit research organization. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals, where he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui has served as a member of the board of directors of ARMO BioSciences, Inc., a publicly-traded immuno-oncology company acquired by Eli Lilly and Company in May 2018, from August 2017 to May 2018, and also currently serves on the boards of directors of several private companies. Dr. Cui holds a Ph.D. in Cancer Biology from Stanford University and a B.S and M.S in Molecular Biology from Peking University.

Christopher Peetz

Mr. Christopher Peetz (Chris) is Independent Director of the company. He has served as a member of our board of directors since April 2018. Mr. Peetz has been the Chief Executive Officer of Flashlight Therapeutics, Inc. and an Entrepreneur-in-Residence at Frazier Healthcare Partners since May 2017. He served as Chief Financial Officer and Head of Corporate Development at Tobira Therapeutics, Inc., a publicly-traded biotechnology company acquired by Allergan plc in November 2016, from May 2014 to December 2016. Prior to joining Tobira Therapeutics, Mr. Peetz served as Vice President, Finance & Corporate Development of Jennerex Biotherapeutics, a private biopharmaceutical company. Prior to Jennerex, Mr. Peetz held various positions at Onyx Pharmaceuticals, Inc. (now Amgen), including oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. Mr. Peetz received an MBA from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.

Paul Sekhri

Mr. Paul Jai Sekhri serves as Independent Director of the Company. He has served as a member of our board of directors since February 2016. Mr. Sekhri is the President and CEO of Lycera Corp., a private biopharmaceutical company, a position he has held since February 2015. Prior to this position, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015, and as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. from March 2013 to March 2014. Prior to joining Teva, Mr. Sekhri spent five years from January 2009 to February 2013, as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital. From 2004 to 2009 Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.

Peter Thompson

Dr. Peter A. Thompson M.D. serves as Independent Director of the Company. He has served as a member of our board of directors since the completion of the Merger in July 2017 and previously served as a member of the board of directors of Private Alpine since June 2016. Dr. Thompson currently serves as a Private Equity Partner for OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he has also served as Venture Partner since joining in September 2010. Dr. Thompson is a co-founder of and has served as a member of the board of directors of Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) since December 2014. Dr. Thompson has also served as a director of Adaptimmune Therapeutics plc (Nasdaq: ADAP), a biopharmaceutical company, since 2014 and also currently serves on the boards of directors of several private companies. Dr. Thompson is a board-certified internist and oncologist and has served as Affiliate Professor of Neurosurgery at the University of Washington since 2010. Dr. Thompson co-founded and served as the Chief Executive Officer of Trubion Pharmaceuticals, Inc., a biopharmaceutical company, from 2002 to 2009. Dr. Thompson previously held executive positions at Chiron Corporation and Becton Dickinson, and served on the faculty of the National Cancer Institute following his medical staff fellowship there. Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.

James Topper

Dr. James N. Topper M.D., Ph.D. serves as Independent Director of the Company. He has served as a member of our board of directors since the completion of the Merger in July 2017 and previously served as a member of the board of directors of Private Alpine since June 2016. Dr. Topper has been a partner with Frazier Healthcare Partners since August 2003, serving as General Partner since 2005. Before joining Frazier Healthcare Partners, Dr. Topper served as head of the Cardiovascular Research and Development Division of Millennium Pharmaceuticals, Inc. and ran Millennium San Francisco (formerly COR Therapeutics, Inc.) from 2002 to 2003. Before the merger of COR and Millennium in 2002, Dr. Topper served as the Vice President of Biology at COR from 1999 to 2002. Dr. Topper currently serves as a member of the board of directors of AnaptysBio, Inc. (Nasdaq: ANAB) and has served on numerous other boards of directors, including Sierra Oncology, Inc. (formerly ProNai) (Nasdaq: SRRA), Amicus Therapeutics, Inc. (Nasdaq: FOLD), Portola Pharmaceuticals, Inc. (Nasdaq: PTLA), and La Jolla Pharmaceutical Company (Nasdaq: LJPC). Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford University and his B.S. in biology from the University of Michigan.

Laurence Watts